Cytodigm Introduces Its PEG-Free Lipid Nanoparticles at LNP Summit

Boston, MA, December 11, 2023 – Victoria Trantow, R&D Scientist at Cytodigm, presented a poster titled “CytofinityTM PEG-free Lipid Nanoparticles for Reduced Immunogenicity” at the 2nd Annual LNP Immunogenicity & Toxicity Summit in Boston, Massachusetts, today. In her poster, she described Cytodigm’s proprietary LNP, CytofinityTM, which uses a novel, patented formulation that allows for the fabrication of colloidally stable LNPs without PEG-lipid, a component found in almost all of today’s LNP formulations. The CytofinityTM LNPs were found to have small sizes (~100 nm), narrow size distribution (PDI < 0.2), and high encapsulation efficiencies (>90%). Various nucleic-acid cargos, such as mRNA and siRNA, were loaded into the LNPs and tested in vitro and in vivo to assess transfection efficiency and toxicity.